Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,074 shares of the medical research company’s stock after acquiring an additional 1,262 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Charles River Laboratories International were worth $2,044,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Versant Capital Management Inc increased its holdings in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. boosted its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. boosted its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International in the third quarter valued at approximately $59,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CRL. Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. Morgan Stanley dropped their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Barclays lowered their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $198.36.

Charles River Laboratories International Trading Up 2.6 %

Shares of NYSE:CRL opened at $171.27 on Monday. The business’s 50 day moving average price is $167.74 and its 200-day moving average price is $184.50. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm has a market capitalization of $8.76 billion, a price-to-earnings ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the company earned $2.46 EPS. The firm’s revenue was down 1.1% compared to the same quarter last year. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).